

AD _____

GRANT NUMBER: DAMD17-94-J-4289

TITLE: Estrogen Metabolism in Breast Cancer Cases and Controls

PRINCIPAL INVESTIGATOR: Giske Ursin, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Southern California
School of Medicine
Los Angeles, California 90033

REPORT DATE: October 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

THIS REPORT CONTAINS

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1995 ⁰⁰	3. REPORT TYPE AND DATES COVERED Annual 1 Oct 94 - 30 Sep 95	
4. TITLE AND SUBTITLE Estrogen Metabolism in Breast Cancer Cases and Controls			5. FUNDING NUMBERS DAMD17-94-J-4289	
6. AUTHOR(S) Giske Ursin, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Southern California School of Medicine Los Angeles, California 90033			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			19960208 148	
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				
12b. DISTRIBUTION CODE				
13. ABSTRACT (Maximum 200 words) It has been suggested that women who metabolize a larger proportion of their natural estrogen via the 16 α -hydroxy pathway may be at significantly elevated risk of breast cancer compared to women who metabolize proportionally more estrogen via the 2-hydroxy pathway. This study evaluates whether the ratios of 16 α -OHE1 to 2-OHE1 are higher in urine of postmenopausal breast cancer cases than in controls; and whether the ratio is elevated in cases independent of total urinary estrone (E1), estradiol (E2) and estriol (E3). Early morning urine samples are collected from 100 breast cancer cases and 100 controls who are participating in an ongoing case-control study of breast cancer at our institution. Five estrogen metabolites in urine are determined: 16 α -OHE1, 2-OHE1, E1, E2 and E3 conjugates. The data collection is in progress.				
14. SUBJECT TERMS estrogen metabolism, 16 α - and 2-hydroxyestrone, urine, breast cancer, case-control study			15. NUMBER OF PAGES 13	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet optical scanning requirements.

Block 1. Agency Use Only (Leave blank).

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

Block 13. Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code (*NTIS only*).

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

✓ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

10/24/95
Date

(4) Table of Contents:

	<u>Pages</u>
(1) Front Cover	1
(2) SF 298 Report Documentation Page	2
(3) Foreword	3
(4) Table of Contents	4
(5) Introduction	5-6
(6) Body	6-10
(7) Conclusions	10
(8) References	10-13

(5) Introduction:

There is overwhelming evidence for a role of ovarian hormones in the etiology of breast cancer (1). At menopause there is a sharp decline in the amount of circulating estrogen, and this decline is at least part of the explanation for the decreased risk associated with early menopause (2). In postmenopausal women, the major source of estrogen arises from the peripheral conversion of androstenedione in adipose tissue (3). This is the most probable explanation for the increased risk of breast cancer associated with obesity in postmenopausal women (4). Elevated serum estrogen levels have been associated with an increased risk of breast cancer in postmenopausal women (5-16). Increased urinary excretion rates of E1, E2 and estriol (E3) have also been found in breast cancer cases as compared with controls (17-24).

The extent to which E2 is metabolized via the 16 α -hydroxylation pathway may also be associated with breast cancer risk (25-27). The two main pathways for metabolizing E2 are via 16 α -hydroxylation and via 2-hydroxylation of E1. The 16 α -metabolites are biologically active (28, 29); the 2-hydroxy-metabolites are not (30). Data demonstrating the difference in biologic activity between 16 α -OHE1 and 2-OHE1 are shown in table 1 (29). Continuous administration of these metabolites to ovariectomized rats resulted in a large weight increase in rats receiving 16 α -OHE1 or estradiol, but very little change in rats receiving 2-OHE1.

Table 1. Effect of continuous estrogen (1 ug/h) in ovariectomized rats on wet uterine weights as percent of control (mean % \pm s.e.) (29).

	Time after implantation		
	24h	48h	72h
Estradiol	165% \pm 15%	363% \pm 20%	490% \pm 22%
16 α -OHE1	155% \pm 7%	365% \pm 16%	552% \pm 42%
2-OHE1	98% \pm 1%	124% \pm 1%	130% \pm 9%

Increased 16 α -hydroxylation, but not 2-hydroxylation activity has been observed in mice strains with high spontaneous mammary tumor formation (25). The extent of biotransformation of ³H-labeled E2 via the 16 α -hydroxylation pathway was found to be 4.6-fold higher in terminal duct lobular units (TDLUs) in breast tissue from breast cancer cases than in breast tissue from reduction mammoplasty controls (31).

The epidemiologic data that address this hypothesis are sparse. Schneider, Bradlow, Fishman and their colleagues injected 33 peri- and postmenopausal breast cancer patients and 10 postmenopausal controls with ³H-labeled estradiol. They found a 60% higher extent of 16 α -hydroxylation among the cases; this difference was statistically significant. There was, however, no statistical difference in 2-hydroxylation between the two groups; 2-hydroxylation was only 5% higher among cases. The ratio of the average level of 16 α -hydroxylation to the average level of 2-hydroxylation was 52% greater in the breast cancer cases than the controls (32). This is the only published study that has examined this aspect of estrogen metabolism and breast cancer risk among postmenopausal women. No data on total estrogen values, dietary or non-dietary risk factors were provided.

The only other study of 16 α -/2-hydroxylation in breast cancer patients was performed by Adlercreutz (33); this study is difficult to interpret. They examined estrogen metabolites in young

premenopausal breast cancer cases (n=10) and controls. The controls were women on an "omnivorous normal Finnish diet" (n=12) or lactovegetarians (n=11). There was no statistical significant difference in total urinary estrogens, 16 α -hydroxylation, 2-hydroxylation or 16 α -/2-hydroxylation between breast cancer patients and omnivores or breast cancer patients and lactovegetarians. The omnivorous women had, however, a higher fat intake than breast cancer patients. Because fat intake has been associated with increased 16 α -hydroxylation (38), this could explain why no differences were found between the omnivores and the cancer patients, but it does not explain the lack of difference between the cancer patients and the vegetarians. The cases and controls were not comparable on parity: 7 of the 10 breast cancer cases, but only 6 of the 23 controls had ever given birth. Whether parity influences the ratio of 16 α -/2-hydroxylation is unknown.

Both of the above mentioned studies measured metabolites after breast cancer diagnosis. Thus there is the possibility that the results obtained in one or both of these studies may have been affected by the cancer or the cancer treatment. In an attempt to determine whether an elevated ratio of 16 α - to 2-hydroxylation precedes diagnosis, Osborne, Bradlow and coworkers studied estrogen metabolism in premenopausal women presumed to be at high or low risk of breast cancer (34). They found that women at 'high risk' of breast cancer (family history of breast cancer or epithelial atypia in a previous biopsy) had a significantly higher (22% higher) extent of 16 α -hydroxylation than women without high risk lesions or a family history ('low-risk' controls). High risk women had a similar elevated extent of 16 α -hydroxylation of E2 as the breast cancer patients in the study described above (32). Translated to relative risks, Osborne et al.'s data suggest that one standard deviation increase in the extent of 16 α -hydroxylation from the level of low risk controls may result in a 3-fold elevation of breast cancer risk. No data on total estrogen values, dietary or non-dietary risk factors were provided. No other studies have been reported attempting to confirm or refute the finding of Osborne et al. (34).

The hypothesis we are testing is whether postmenopausal women with breast cancer metabolize a significantly higher amount of E1 through 16 α - than 2-hydroxylation compared to postmenopausal controls, independent of total urinary E1, E2 and E3. We expect the ratios of 16 α -hydroxy-metabolites to 2-hydroxy-metabolites to be statistically significantly higher in cases than in controls.

(6) Body:

METHODS

The methods we are using to obtain the sample are as follows:

Case selection: 100 cases will be selected using the criteria defined below:

Case selection- Eligibility Criteria:

1. Incident cases of female breast cancer identified through the Los Angeles County Cancer Surveillance Program (CSP; an NCI SEER registry), aged 55-64 years at time of diagnosis of histologically confirmed breast cancer.
2. Cancer \leq stage II [tumor size \leq T₂, nodes \leq N₁, no distant metastasis (M₀), or T₃, N₀, M₀] (40).
3. A participant in an ongoing breast cancer case-control study at our institution (P.I. R. Ross, NIH 5 P01 CA 17054).

4. English speaking, Black or White (including Hispanic), resident in Los Angeles County at time of the case's diagnosis.
5. Over the past 6 months: not used medications that may interfere with estrogen metabolism (cimetidine, thyroxine, estrogen, progesterone, tamoxifen, or omega-3 fatty acid supplements).
6. Over the past 3 months: not have had general anesthesia.

Control selection:

We will enroll 100 controls from the non-cancer control group used for the breast cancer case-control study who satisfy eligibility criteria 3-9 above. (No further matching on age is necessary, since all participants are between 55-64 years of age). There will be no matching on weight, but we will adjust for weight in the statistical analysis of the results.

Recruitment procedures:

The research scientist will contact cases and controls who were most recently interviewed for the ongoing study, and then subsequently systematically contact women who participated previously. Cases and controls will be contacted strictly in order of recency of interview. Cases and controls who have moved are attempted to be traced through the Department of Motor Vehicle (DMV) files. Letters are sent to new addresses when these are obtained. Cases and controls are asked to provide a 60 ml sample of first void early morning urine. Thus, the first 100 cases and the first 100 controls identified from this process who satisfy the eligibility criteria and are willing to sign an informed consent are included.

A box containing a 100 ml urine vial with a 100 mg ascorbate tablet, a small cooler with multiple ice packs (only leaving room for the urine sample), an informed consent form and a questionnaire on recent intake of medication, alcohol and specific foods are shipped to each eligible woman who agrees to participate. The participants will be asked to place the urine sample in the cooler with the ice packs (previously frozen by the participant) immediately after it has been produced, and to enclose a signed informed consent form and the completed questionnaire on alcohol intake and current medication with the cooler.

For approximately half the participants the cooler with the urine has been picked up (by noon) the same day the urine sample is produced. For the other half of the participants the samples have been shipped with overnight express mail. The urine samples are divided into two samples of approximately 15 ml and immediately frozen at -70°C until shipped to the processing laboratories.

Dietary questionnaires and stamped return envelopes are sent to the participants after the urine has been received.

Batches of 30 samples, 15 from cases, 15 from controls are coded and shipped on dry ice via overnight express mail to Dr. Bradlow at the Strang-Cornell Cancer Research Laboratory, where the $16\alpha\text{-OHE1}$ and 2-OHE1 assays will be performed. At the same time as samples are shipped to Dr. Bradlow, we will also ship samples to Dr. Stanczyk at Los Angeles County/USC Women's Hospital, who will perform the E1, E2 and E3 assays. The only identifiers on the samples are code numbers ensuring that the laboratories will be blinded as to case or control status of the individual samples.

LABORATORY METHODS

The 16a-OHE1 and 2-OHE1 assays will be performed by Dr. H. Leon Bradlow at Strang-Cornell Cancer Research Laboratory in New York. The E1, E2 and E3 assays will be performed by Dr. Frank Stanczyk at the Reproductive Endocrinology Laboratory at the Los Angeles County/USC Women's Hospital.

Enzyme Immunoassay (EIA) of 16a-OHE1 and 2-OHE1:

This method has been described and validated by Klug et al. (41). In short, the EIAs used for these assays (Immuna Care Corporation, Bethlehem, PA) are competitive, solid-phase immunoassays. In this assay format, the antibody is immobilized on the solid phase and the antigen (estrogen metabolite) is labeled with the enzyme. In the test, binding of the antigen-enzyme conjugate by the immobilized antibody is inhibited by the addition of free antigen. Since a restricted number of antibody binding sites are available, the enzyme activity bound to the solid phase in the presence of free antigen is lowered. When enzyme substrate is added to the washed solid phase, the enzyme product (e.g., colored dye) concentration is inversely proportional to the concentration of the free antigen. In the current assay kits, monoclonal antibodies to estrogen metabolites are immobilized directly to the solid phase (wells of 8 x 12 polystyrene microtiter phase). The estrogen metabolites have been conjugated to alkaline phosphatase enzyme (AP).

The estrogens are deconjugated of both glucuronic acid and sulphate by use of a mixture of β -glucuronidase and arylsulphatase enzyme isolated from the snail *Helix Pomatia*. An aliquot of urine is diluted 1:20 with an acid buffer containing the enzymes and incubated until deconjugation is complete. The enzyme digest is then neutralized and used directly in the assay.

The intraassay (within assay) coefficients of variation (CVs) and the interassay (between-assay) CV for the two assays are all between 5-10%.

The EIA kits for urinary 16a-OHE1 and 2-OHE1 have been validated by comparing values obtained with these kits to values obtained by Gas Chromatography-Mass Spectroscopy (42). The correlation coefficient between the two methods was found to be 0.80 for both 16a-OHE1 and 2-OHE1.

Radioimmunoassay of Urinary E1, E2 and E3:

Urine (1 ml) is acidified with 2M acetate buffer (pH 5) and a mixture of β -glucuronidase/arylsulfatase is added to hydrolyze estrogen conjugates. Deconjugation is carried out during a 24 hour incubation period at 37°C. Following the addition of approximately 1000 d.p.m. of ^3H -E1, ^3H -E2, and ^3H -E3, which serve as internal standards to follow procedural losses, a selective extraction of E1, and E2, is carried out using diethyl ether (43). E3, which remains in the aqueous layer, is removed by extraction with 40% ethyl acetate in hexane.

The estrogens in the crude extracts are chromatographed using different solvent systems. E1 and E2 are applied on a column of Celite impregnated with ethylene glycol. E1 is eluted in 3.5 ml of 15% ethyl acetate in isooctane, and E2 in 5 ml of 50% ethyl acetate in isooctane. Similarly, the ethyl acetate/isooctane mixture containing E3 is applied on a column of Celite (impregnated with methanol: water (60:40::v:v). E3 is eluted with 30% ethyl acetate in isooctane.

The E1, E2 and E3 fractions are quantified by radioimmunoassay (RIA) using methods previously described by Stanczyk and colleagues (43-45). Separation of the antibody-bound and unbound estrogens is accomplished by either dextran-coated charcoal or double antibody techniques, employing standard procedures. The estrogen RIAs have been validated as described

previously (43-45). Appropriate quality controls are used with each set of samples that is assayed to monitor assay reliability. The intraassay and interassay CVs of each estrogen RIA are 5-10% and 10-15%, respectively.

Dietary Assessment:

Dietary factors may influence the extent of 16 α - and 2-hydroxylation (46-48). We are therefore collecting data on dietary intake (including alcohol) over the past year using the dietary questionnaire developed by Dr. Willett and coworkers (49-50). In addition, information on medication and alcohol intake over the previous 48 hours as well as alcohol intake over the past month will be collected. We will also ask about the consumption of foods high in indole-3-carbinol over the past 48 hours.

STATISTICAL ANALYSIS

Results will be analyzed statistically using t-tests, standard analyses of covariance techniques, as well as logistic regression (51-54) using the statistical software packages SAS (SAS Institute Inc., Cary, NC) and EPILOG (Epicenter Software, Pasadena, CA). In the logistic regression, the odds ratio per unit increase in 16 α -OHE1/2-OHE1, (16 α -OHE1 + E3)/2-OHE1 and E3/2-OHE1 (with and without adjustment for urinary E1, E2 and E3), will be calculated. Other variables that will be considered as possible confounders are: age, race, body mass index, age at first birth, parity, age at and type of menopause, and dietary intake (such as total fat, protein, carbohydrate and alcohol intake).

RESULTS

We have so far contacted 407 cases and 445 controls. Responses have been obtained from approximately 700 women so far. Approximately 170 subjects (20%) have been found to be eligible so far. Major reasons for ineligibility are tamoxifen use (35% of cases) and estrogen use (38% of controls). Other reasons for ineligibility include: use of other medications (chemotherapy, thyroid medication etc.) (20%), moved, and not traceable through DMV (10%), refusal (5%), deceased (5% of cases), other (weight, recent surgery etc.) 10%. Currently, urine samples have been collected from 157 subjects (71 cases and 86 controls). This represents approximately 80% of the samples we said we would collect. The number of ineligible women, and the number of women who had moved and who therefore had to be traced through the DMV was higher than expected. There are some women who we have just recently localized through the DMV, and who have therefore only been contacted once. We have now just started recontacting these women. We are also in the process of identifying all other nonresponders and will contact them shortly. This should increase our number of eligible women to 200.

The first batches of urine samples have been sent to Dr. Bradlow in New York and Dr. Stanczyk at USC for analysis. Preliminary results of urine samples from the first 55 subjects did not yield significant differences between cases and controls on 16 α -/2-OHE1. (The differences between cases and controls on E1, E2, E3 or the combination of the three were not quite statistically significant). However, because our study coincided with a reproducibility/validity study of the EIA assays of 16 α - and 2-OHE1 conducted by Dr. Regina Ziegler, NCI, we decided earlier this spring to wait with our urinary analyses until the results from Dr. Ziegler's study were

available. Dr. Ziegler and coworkers found that the reproducibility of the assays of 16α - and 2-OHE1 in postmenopausal women was rather low (Regina Ziegler, NCI, unpublished data). As a result of this, the 16α - and 2-OHE1 assays have during the past few months undergone adjustments to account for the lower levels of estrogens in urine of postmenopausal women (Leon Bradlow, personal communication). The new, adjusted assays are currently being validated by Ziegler and colleagues at NCI. We have therefore decided to wait with sending further samples until the results of Dr. Ziegler's study suggests that the reproducibility of the assays has been improved. We expect these problems to be resolved within a few months. Because of these reproducibility problems of the EIAs for 16α -OHE1 and 2-OHE1, we requested (and have obtained) a 1-year no-cost extension of this grant.

The questionnaires are checked for inconsistencies as they are obtained. The dietary questionnaires are normally shipped in batches of 100 to Harvard. As we are collecting data on 200 women, we have therefore decided to wait with sending these to Harvard until all the questionnaires have been collected. The other risk factor information obtained for this study is being prepared for key-punching. The data will be key-punched all at one time when all the urine samples have been collected.

(7) Conclusions

Because of the reproducibility problems with the 16α - and 2-OHE1 assays discussed above, we would prefer to not draw any implications from our results so far. It is also too early to suggest changes for future projects, except perhaps that it would be useful to request funds for a separate validity/reproducibility study if a new method is being used.

(8) References

1. Henderson BE, Ross RK, Bernstein L. Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. *Cancer Res* 1988;48:246-53.
2. Trichopoulos D, MacMahon B, Cole P. The menopause and breast cancer. *J Natl Cancer Inst* 1972;48:605-13.
3. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. *J Clin Endocrinol Metab* 1973;36:307-14.
4. Lubin F, Ruder AM, Wax Y, Modan B. Overweight and changes in weight throughout adult life in breast cancer etiology. *Am J Epidemiol* 1985;122:579-88.
5. England PC, Skinner LG, Cottrell KM, Sellwood RA. Serum estradiol- 17β in women with benign and malignant breast disease. *Br J Cancer* 1974;30:571-6.
6. McFadyen IJ, Prescott RJ, Groom GV, Forrest APM, Golder MP, Fahmy DR. Circulating hormone concentrations in women with breast cancer. *Lancet* 1976;ii:1100-2.
7. Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. *Cancer Res* 1977;37:4655-59.
8. Adami HO, Johansson EDB, Vegelius J, Victor A. Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls. *Upsala J Med Sci* 1979;84:259-74.

9. Drafta D, Schindler AF, Milicu M, Keller E, Stroe E, Horodniceanu E, Balanescu I. Plasma hormones in pre- and postmenopausal breast cancer. *J Steroid Biochem* 1980;43:793-802.
10. Moore JW, Clark GMG, Bulbrook RD, Hayward JL, Murai JT, Hammond GL, Siiteri PK. Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls. *Int J Cancer* 1982;29:17-21.
11. Reed MJ, Cheng RW, Noel CT, Dudley HAF, James VHT. Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. *Cancer Res* 1983;43:3940-43.
12. Reed MJ, Beranek PA, Cheng RW, Ghilchik MW, James VHT. The distribution of oestradiol in plasma from postmenopausal women with or without breast cancer: relationships with metabolic clearance rates of oestradiol. *Int J Cancer* 1985;35:457-60.
13. Secreto G, Recchione C, Cavalleri, Miraglia M, Dati V. Circulating levels of testosterone, 17 β -oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. *Br J Cancer* 1983;47:269-75.
14. Bruning PF, Bonfrer JMG, Hart, AAM. Non-protein bound oestradiol, sex hormone binding globulin and breast cancer risk. *Br J Cancer* 1985;51:479-84.
15. Siiteri PK, Simberg N, Murai J. Estrogens and breast cancer. *Ann NY Acad Sci* 1986;464:100-5.
16. Wysowski DK, Comstock G W, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. *Am J Epidemiol* 1987;25:791-99.
17. Persson BH, Risholm L. Oophorectomy and cortisone treatment as a method of eliminating estrogen production in patients with breast cancer. *Acta Endocrinol* 1964;47:15-26.
18. Marmorston J, Crowley LG, Myers SM, Stern E, Hopkins CE. II. Urinary excretion of estrone, estradiol, and estriol by patients with breast cancer and benign breast disease. *Am J Obstet Gynecol* 1965;4:460-467.
19. Arguelles AE, Hoffman C, Poggi UL, Chekherdemian M, Saborida C, Blanchard O. Endocrine profiles and breast cancer. *Lancet* 1973;i:165-67.
20. Gronroos M, Aho AJ. Estrogen metabolism in postmenopausal women with primary and recurrent breast cancer. *Europ J Cancer* 1968;4:523-27.
21. Grattarola R, Secreto G, Recchione C, Castellini W. Androgens in breast cancer. *Am J Obstet Gynecol* 1974;118:173-78.
22. Thijssen JHH, Poortman J, Schwarz F. Androgens in postmenopausal breast cancer; excretion, production and interaction with estrogens. *J Steroid Biochem* 1975;6:729-34.
23. Morreal CE, Dao TL, Nemoto T, Lonergan PA. Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer. *J Natl Cancer Inst* 1979;63:1171-74.
24. Bernstein L, Ross RK, Pike MC, Brown JB, Henderson BE. Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. *Br.J.Cancer* 1990;61:298-302.
25. Bradlow HL, Hershcopf RE, Fishman JF. Oestradiol 16 α -hydroxylase: a risk marker for breast cancer. *Cancer Surv* 1986;5:574-83.
26. Bradlow HL, Hershcopf R, Martucci C, Fishman J. 16 α -hydroxylation of estradiol: A possible risk marker for breast cancer. *Ann NY Acad Sci* 1986;464:138-51.
27. Bradlow HL, Hershcopf RE, Martucci CP, Fishman J. Estradiol 16 α -hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary

- tumor virus: A possible model for the hormonal etiology of breast cancer in humans. *Proc Natl Acad Sci USA*;1985;82:6295-99.
28. Clark JH, Paszko Z, Peck EJ Jr. Nuclear binding and retention of the receptor estrogen complex:relation to the agonistic and antagonistic properties of estriol. *Endocrinol* 1977;100:91-96.
29. Fishman J, Martucci C. Biological properties of 16 α -hydroxyoestrone:implications in estrogen physiology and pathophysiology. *J Clin Endocrin Metab* 1980;51:611-15.
30. Martucci C, Fishman J. Direction of estradiol metabolism as a control of its hormonal action - uterotrophic activity of estradiol metabolites. *Endocrinol* 1977;101:1709-15.
31. Schneider J, Kinne D, Fracchia A, Pierce V, Bradlow HL, Fishman J. Abnormal oxidative metabolism of estradiol in women with breast cancer. *Proc Natl Acad Sci USA*;1982;79:3047-51.
32. Osborne MP, Karmali RA, Hershcopf RJ, Bradlow HL, Kourides IA, Williams WR, Rosen PP, Fishman J. Omega-3 fatty acids:modulation of estrogen metabolism and potential for breast cancer prevention. *Cancer Invest* 1988;8:629-31.
33. Fishman J, Boyar RM, Hellman L. Influence of body weight on estradiol metabolism in young women. *J Clin Endocrinol Metab* 1975;41:989-91.
34. Schneider J, Bradlow HL, Strain G, Levin J, Anderson K, Fishman J. Effects of obesity on estradiol metabolism:Decreased formation of nonuterotropic metabolites. *J Clin Endocrin Metab* 1983;56:973-78.
35. Snow RC, Barbieri RL, Frisch RE. Estrogen 2-Hydroxylase oxidation and menstrual function among elite oraswomen. *J Clin Endocrinol Metab* 1989;69:369-76.
36. Musey PI, Collins DC, Bradlow HL, Gould KG, Preedy JRK. Effect of diet on oxidation of 17 β -estradiol in vivo. *J Clin Endocrinol Metab* 1987;65:792-95.
37. Michnovicz JJ, Bradlow HL. Altered estrogen metabolism and excretion in human following consumption of indole-3-carbinol. *Nutr Cancer* 1991;16:59-66.
38. Hoffman AR, Majchrowicz E, Poth A, Paul SM. Ethanol reduces hepatic estrogen-2-hydroxylase activity in the male rat. *Life Sciences* 1981;29:789-94.
39. Michnovicz JJ, Hershcopf RJ, Naganauma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. *N Engl J Med* 1986;315:1305-9.
40. Bland KI, Copeland III, EM. *The Breast: Comprehensive Management of Benign and Malignant Diseases*. W.B. Saunders Company, Philadelphia: Pennsylvania, 1991.
41. Klug TL, Bradlow HL, Sepkovic. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2-and 16 α -hydroxyestrone in urine. *Steroids* 1994;59:648-55.
42. Adlercreutz H, Martin F, Wahlroos Ö, Soini E. Mass spectrometric and mass fragmentographic determination of natural and synthetic steroids in biological fluids. *J Steroids Biochem* 1975;6:247-59.
43. Katagiri H, Stanczyk FZ, Goebelsmann U. Estriol in pregnancy. III. Development, comparison and use of specific antisera for rapid radioimmunoassay of unconjugated esrtiol in pregnancy plasma. *Steroids* 1974;24:225-38.
44. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of nonoral estradiol delivery in postmenopausal women. *Am J Obstet Gynecol* 1988;159:1540-46.

45. Cassidenti DL, Vijod AG, Vijod MA, Stanczyk FZ, Lobo RA. Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. *Am J Obstet Gynecol* 1990;163:1953-60.
46. Musey PI, Collins DC, Bradlow HL, Gould KG, Preedy JRK. Effect of diet on oxidation of 17 β -estradiol in vivo. *J Clin Endocrinol Metab* 1987;65:792-95.
47. Michnovicz JJ, Bradlow HL. Altered estrogen metabolism and excretion in human following consumption of indole-3-carbinol. *Nutr Cancer* 1991;16:59-66.
48. Hoffman AR, Majchrowicz E, Poth A, Paul SM. Ethanol reduces hepatic estrogen-2-hydroxylase activity in the male rat. *Life Sciences* 1981;29:789-94.
49. Willett WC, Stampfer MJ, Underwood BA, Speizer FE, Rosner B, Hennekens CH. Validation of a dietary questionnaire with plasma carotenoid and alpha-tocopherol levels. *Am J Clin Nutr* 1983;88:631-39.
50. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE. Reproducibility and validity of a semiquantitative food frequency questionnaire. *Am J Epidemiol* 1985;122:51-65.
51. Breslow NE, Day NE. *Statistical Methods in Cancer Research. Volume 1- The analysis of case-control studies.* IARC Scientific Publication No. 32. Lyon 1980.
52. Rosner B. *Fundamentals of Biostatistics. Third Edition.* PWS-Kent Publishing Company. Boston, Massachusetts, 1990.
53. Kleinbaum DG, Kupper LL, Morgenstern H. *Epidemiologic Research.* Van Nostrand Reinhold Company. New York 1982.
54. Rothman KJ. *Modern Epidemiology.* Little, Brown and Company. Boston/Toronto 1986.